Industry cites outdated standards as flaw in FDA’s real-world data draft guidance
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyNorth AmericaPharmaceuticalsRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesBiotechnologyNorth AmericaPharmaceuticals